Avalo Therapeutics enters up to $200 million at-the-market offering agreement with Jefferies
AVTX•Avalo Therapeutics entered an agreement with Jefferies to sell up to $200 million of common stock through at-the-market offerings, at the company’s discretion. Jefferies may receive a commission of up to 3% of gross sale proceeds.
1. Offering terms
Avalo Therapeutics entered the agreement on November 5, 2026. The company has no obligation to sell shares. Its prior sales agreement with TD Cowen, dated June 5, 2025, terminated effective November 5, 2026.
